Study of Safety Pharmacokinetics and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

  • STATUS
    Recruiting
  • participants needed
    69
  • sponsor
    MapKure, LLC
Send
Updated on 16 February 2024
See if I qualify
cancer
measurable disease
lung cancer
solid tumor
sarcoma
cancer treatment
solid neoplasm
metastatic malignant solid tumor
colorectal cancer
melanoma
non-small cell lung cancer
small cell lung cancer

Summary

The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of BGB-3245 in participants with advanced or refractory tumors harboring specific v-RAF murine sarcoma viral oncogene homolog B (B-RAF) genetic mutations.

Description

This is a first-in-human, Phase 1a/1b (dose escalation and expansion) study of BGB-3245 in participants with tumors harboring B-RAF mutations that are likely to respond to a RAF dimer inhibitor. BGB-3245 is a second-generation B-RAF inhibitor that has demonstrated potent inhibitory activity against the RAF family of serine/threonine kinases preclinically. In preclinical studies, BGB-3245 showed it inhibited tumor cell lines harboring non-V600 B-RAF mutations; it was also active towards B-RAF/MAP-ERK Kinase (MEK) inhibitor-resistant tumors.

Phase 1a will consist of a dose-escalation and dose-finding component to establish the MTD and/or RP2D and to evaluate the pharmacokinetics of BGB-3245 3245 in participants with MAPK pathway aberrations. Phase 1b will consist of an expansion component to further evaluate the pharmacokinetics, safety, and tolerability of BGB-3245 at the RP2D and to assess the preliminary antitumor activity of the compound in participants with select tumor types and B-RAF mutational status.

Details
Condition Solid Tumor, B-Raf Mutation-Related Tumors
Age 18years - 100years
Treatment BGB-3245
Clinical Study IdentifierNCT04249843
SponsorMapKure, LLC
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Participants with histologically or cytologically confirmed advanced or metastatic solid tumor who have experienced disease progression during or after at least 1 line of prior systemic anticancer therapy, or for whom treatment is not available or not tolerated/acceptable to the participants. In addition, participants must meet the following eligibility criteria for the corresponding phase of the study
Phase 1a: Participants with a known mutation status and tumor harboring an oncogenic B-RAF or K-RAS/N-RAS mutation, or any other MAPK pathway aberrations. In Phase 1a, the study recruitment will be limited to approximately one third (1/3) participants with K-RAS/N-RAS mutation, and among these participants the study recruitment will be limited to approximately one third (1/3) colorectal cancer (CRC) or pancreatic participants
Phase 1b: participants must have a known mutation status and meet one of the following criteria according to the group they are enrolled into
Group 1: participants with solid tumors with non-V600 B-RAF mutations including RAF fusions,; or
Group 2: participants with B-RAF V600 mutated melanoma or non-small cell lung cancer (NSCLC), and have progressed on a B-RAF-inhibitor and/or MEK-inhibitor resistant tumors (i.e., mitogen-activated protein kinase/extracellular signal regulated kinase) inhibitor resistant tumors
Participants must provide tumor tissue sample (archival tumor tissue or agree to a fresh tumor biopsy) for mutation and biomarkers analysis 3. Participants must have measurable disease as defined per RECIST v1.1. 4. Eastern Cooperative Oncology Group performance status of 1 at Screening. 5. Adequate hematologic and organ function, as indicated by the following laboratory values, prior to Cycle 1 Day 1

Exclusion Criteria

Participants receiving cancer therapy (chemotherapy or other systemic anticancer therapies, immunotherapy, radiation therapy, or surgery) at the time of Cycle 1 Day 1
All participants who have received prior systemic anticancer treatment within the following time frames will be excluded
Cyclical chemotherapy within a period of time that is shorter than the cycle length used for that treatment (i.e., 6 weeks for nitrosourea, mitomycin C) prior to Cycle 1 Day 1; and
Biologic therapy (i.e., antibodies), continuous or intermittent small-molecule therapies, or any other investigational agents within a period of 5 times the half-life of the agent or 4 weeks (whichever is shorter) prior to Cycle 1 Day 1
History or presence of gastrointestinal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs
Leptomeningeal disease or untreated/unstable brain metastasis except participants with previously treated brain metastasis who are radiologically stable (imaging evidence required), asymptomatic and have been off steroids and antiseizure medications for longer than 28 days prior to Cycle 1 Day 1 are permitted
Any unstable, preexisting major medical condition that in the opinion of the investigator contraindicates the use of an IMP, including known human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Participants who are hepatitis B surface antigen (HBsAg) positive or HCV antibody positive at Screening may be enrolled only if HBV DNA titers <500 IU/mL or negative HCV RNA polymerase chain reaction test, respectively
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
measurable disease
lung cancer
solid tumor
sarcoma
cancer treatment
solid neoplasm
metastatic malignant solid tumor
colorectal cancer
melanoma
non-small cell lung cancer
small cell lung cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.